Who is sponsoring NCT06613945?

NCT06613945 is sponsored by Mansoura University.

What drugs are being tested in NCT06613945?

Interventions in NCT06613945: ERCP biliary drainage, Combined ERCP and EUS-HGS biliary drainage.

What condition does NCT06613945 study?

NCT06613945 studies Malignant Hilar Stricture.

Is NCT06613945 still recruiting?

NCT06613945 is currently recruiting now. Last updated 26 September 2024.

Last reviewed 2024-09-26 · How we verify

NCT06613945

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ERCP With and Without EUS Guided HGS for Bilateral Biliary Decompression in Malignant Hilar Biliary Obstruction

Recruiting now NA Last updated 26 September 2024

What this trial tests

NA trial testing ERCP biliary drainage in Malignant Hilar Stricture in 72 participants. Currently enrolling.

Timeline

1 September 2024

Primary endpoint
30 October 2025

30 October 2026

Quick facts

Lead sponsor	Mansoura University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	72
Start date	1 September 2024
Primary completion	30 October 2025
Estimated completion	30 October 2026
Sites	1 location across Egypt

Drugs / interventions tested

ERCP biliary drainage
Combined ERCP and EUS-HGS biliary drainage

Conditions studied

Malignant Hilar Stricture — all drugs for Malignant Hilar Stricture →

Sponsor

Mansoura University

Who can join

18 and older, any sex, with Malignant Hilar Stricture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective randomized clinical trial to evaluate efficacy and safety of combined EUS-HGS and ERCP compared to ERCP for bilateral biliary decompression in advanced malignant hilar biliary obstruction. The primary outcome will be technical success, clinical success, procedural duration, and re-interventions. Secondary outcomes will be the rate of adverse events. patients will be followed up at 1 and 3 month intervals

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Mansoura University trials

Trials by the same sponsor.

NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06613945 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mansoura University
Last refreshed: 26 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06613945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing